Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I. Machida Y, et al. Among authors: nakagawa m. Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727689
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M, Fujita S, Katsumoto T, Yamagata K, Ogawara Y, Hattori A, Kagiyama Y, Honma D, Araki K, Inoue T, Kato A, Inaki K, Wada C, Ono Y, Yamamoto M, Miura O, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Cancer Sci. 2019 Jan;110(1):194-208. doi: 10.1111/cas.13840. Epub 2018 Nov 16. Cancer Sci. 2019. PMID: 30343511 Free PMC article.
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, Machida Y, Katsumoto T, Yamagata K, Hattori A, Fujita S, Aikawa Y, Ishikawa T, Soga T, Kawai A, Chuman H, Yokoyama N, Fukushima S, Yahiro K, Kimura A, Shimada E, Hirose T, Fujiwara T, Setsu N, Matsumoto Y, Iwamoto Y, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12. Oncogene. 2019. PMID: 31406254
CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, Honma D, Adachi N, Araki K, Kato A, Inaki K, Ono Y, Fukuhara S, Kobayashi Y, Tobinai K, Kitabayashi I. Kagiyama Y, et al. Among authors: nakagawa m. Cancer Sci. 2021 Jun;112(6):2314-2324. doi: 10.1111/cas.14905. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33792119 Free PMC article.
Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M, Sekimizu M, Endo M, Kobayashi E, Iwata S, Fukushima S, Yoshida A, Kitabayashi I, Ichikawa H, Kawai A, Nakatani F. Nakagawa M, et al. J Orthop Sci. 2022 Nov;27(6):1315-1322. doi: 10.1016/j.jos.2021.07.024. Epub 2021 Sep 14. J Orthop Sci. 2022. PMID: 34531086
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.
Shinohara H, Sawado R, Nakagawa M, Hattori A, Yamagata K, Tauchi K, Ito J, Kuwahara Y, Okuda T, Ogawa C, Kitabayashi I. Shinohara H, et al. Among authors: nakagawa m. Mol Ther Oncolytics. 2022 Sep 19;27:14-25. doi: 10.1016/j.omto.2022.09.006. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36212776 Free PMC article.
Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma.
Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C. Ogiwara Y, et al. Among authors: nakagawa m. Cancer Lett. 2022 Jul 1;537:215690. doi: 10.1016/j.canlet.2022.215690. Epub 2022 Apr 16. Cancer Lett. 2022. PMID: 35439537
3,978 results